Ablynx nv

Ablynx, a biopharmaceutical company with headquarters in Ghent, Belgium, is engaged in the discovery and development of Nanobodies® to treat a range of serious human diseases. Nanobodies® are a novel class of antibody-derived therapeutic proteins. Because of their small size, unique structure and extreme stability, Nanobodies® combine the advantages of conventional antibody therapeutics with the key features of small-molecule drugs.

Website

Technologiepark 4
Ghent/Zwijnaarde 9052 Belgium
+32 (0)9 262 00 00